{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T06:32:17Z","timestamp":1775543537407,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Practical Research Project","award":["JP16ek0510004"],"award-info":[{"award-number":["JP16ek0510004"]}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.bbmt.2017.11.016","type":"journal-article","created":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T00:32:55Z","timestamp":1511915575000},"page":"840-848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Prognostic Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in Adults with Chronic Myelomonocytic Leukemia: A Nationwide Retrospective Analysis in Japan"],"prefix":"10.1016","volume":"24","author":[{"given":"Hidehiro","family":"Itonaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunari","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Sakura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuteru","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mineo","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiyasu","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinori","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Iwato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Nawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Hirokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Ichinohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2017.11.016_bib0010","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"76","article-title":"Chronic myelomonocytic leukemia","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0015","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0020","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients","volume":"99","author":"Onida","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0025","first-page":"107","article-title":"Chronic myelomonocytic leukemia","volume":"142","author":"Beran","year":"2008","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0030","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/1042819042000207271","article-title":"Risk assessment in chronic myelomonocytic leukemia (CMML)","volume":"45","author":"Germing","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0145-2126(97)00149-5","article-title":"Treatment with low-dose oral etoposide in patients with myelodysplastic syndromes","volume":"22","author":"Doll","year":"1998","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0040","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.1999.17.9.2819","article-title":"Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"17","author":"Beran","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0045","first-page":"139","article-title":"Intensive chemotherapy for patients with high-risk myelodysplastic syndrome","volume":"72","author":"Beran","year":"2000","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0050","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.leukres.2007.08.004","article-title":"Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)","volume":"32","author":"Wijermans","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0055","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/cncr.25759","article-title":"Activity of azacitidine in chronic myelomonocytic leukemia","volume":"117","author":"Costa","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0060","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/leu.2014.85","article-title":"A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia","volume":"28","author":"Drummond","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0065","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/sj.bmt.1705369","article-title":"Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia","volume":"37","author":"Elliott","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0070","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/bmt.2009.375","article-title":"Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience","volume":"45","author":"Krishnamurthy","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0075","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/ejh.12073","article-title":"Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"90","author":"Park","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0080","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2141.2002.03552.x","article-title":"Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"118","author":"Kr\u00f6ger","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0085","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.bbmt.2010.09.018","article-title":"Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities","volume":"17","author":"Eissa","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0090","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.bmt.1704472","article-title":"Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative\/BCR-ABL-negative chronic myelogenous leukemia","volume":"33","author":"Mittal","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0095","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/bmt.2008.366","article-title":"Outcome of allo-SCT for chronic myelomonocytic leukemia","volume":"43","author":"Ocheni","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0100","doi-asserted-by":"crossref","unstructured":"Symeonidis A., van Biezen A., de Wreede L., et\u00a0al. Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation [e-pub ahead of print]. Br J Haematol. doi:10.1111\/bjh.13576, accessed December 19, 2017.","DOI":"10.1111\/bjh.13576"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0105","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.bbmt.2017.01.078","article-title":"Allogeneic hematopoietic cell transplantation for adult chronic myelomonocytic leukemia","volume":"23","author":"Liu","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0110","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.leukres.2015.12.009","article-title":"Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: a nationwide retrospective study","volume":"41","author":"Itonaga","year":"2016","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0115","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1532\/IJH97.06239","article-title":"Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System","volume":"86","author":"Atsuta","year":"2007","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","article-title":"Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data)","volume":"103","author":"Atsuta","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12185-015-1907-9","article-title":"Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation","volume":"103","author":"Kanda","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0130","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.3324\/haematol.2016.149427","article-title":"Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups","volume":"101","author":"Inamoto","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0135","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3324\/haematol.2015.136903","article-title":"High-risk HLA alleles for severe acute graft-versus-host disease and mortality in unrelated donor bone marrow transplantation","volume":"101","author":"Morishima","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0140","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1182\/blood-2008-03-147041","article-title":"Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia","volume":"113","author":"Atsuta","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0145","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0150","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2006-05-021907","article-title":"Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)","volume":"109","author":"Estey","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0155","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/bjh.13124","article-title":"Allogeneic haematopoietic cell transplantation with reduced-intensity conditioning for elderly patients with advanced myelodysplastic syndromes: a nationwide study","volume":"168","author":"Aoki","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0160","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0165","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0170","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0175","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0180","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1200\/JCO.2014.57.2446","article-title":"Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation","volume":"33","author":"Eapen","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0185","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3324\/haematol.2015.135699","article-title":"Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT","volume":"101","author":"Savani","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0190","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1056\/NEJMoa041276","article-title":"Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia","volume":"351","author":"Laughlin","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0195","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1056\/NEJMoa041469","article-title":"Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia","volume":"351","author":"Rocha","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0200","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.bbmt.2008.03.003","article-title":"Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases","volume":"14","author":"Uchida","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0205","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1182\/blood-2004-03-1001","article-title":"Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies","volume":"104","author":"Takahashi","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0210","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/bmt.2008.164","article-title":"Unrelated cord blood transplantation in CML: Japan Cord Blood Bank Network analysis","volume":"42","author":"Nagamura-Inoue","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0215","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1182\/blood-2003-05-1597","article-title":"Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation","volume":"102","author":"Fukuda","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0220","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.bbmt.2009.12.534","article-title":"Strong association between respiratory viral infection early after hematopoietic stem cell transplantation and the development of life-threatening acute and chronic alloimmune lung syndromes","volume":"16","author":"Versluys","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0225","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12026-009-8139-0","article-title":"High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation","volume":"47","author":"Luznik","year":"2010","journal-title":"Immunol Res"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0230","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","article-title":"Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning","volume":"19","author":"Raiola","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0235","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/ajh.23392","article-title":"In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation","volume":"88","author":"Kanda","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0240","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2006.07.0953","article-title":"Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution","volume":"25","author":"Rizzieri","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0245","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/leu.2012.203","article-title":"Unrelated cord blood transplantation vs related transplantation with HLA 1-antigen mismatch in the graft-versus-host direction","volume":"27","author":"Kanda","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0250","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1182\/blood-2011-02-339838","article-title":"Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome","volume":"118","author":"Lee","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0255","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbmt.2015.08.031","article-title":"Treatment with hypomethylating agents before allogeneic stem cell transplant improves progression-free survival for patients with chronic myelomonocytic leukemia","volume":"22","author":"Kongtim","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.016_bib0260","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","article-title":"Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation","volume":"129","author":"Yoshizato","year":"2017","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117308625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117308625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:02:40Z","timestamp":1761058960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879117308625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1083879117308625"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.11.016","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in Adults with Chronic Myelomonocytic Leukemia: A Nationwide Retrospective Analysis in Japan","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}